Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com
Lena Trautmann
Director Investor Relations & Sustainability
T: +49 (0) 6172 608-4105
lena.trautmann@fresenius.com
Michael Otto
Director Investor Relations
T: +49 (0) 6172 608-2419
michael.otto@fresenius.com
Axel Faupel
Director Investor Relations & Sustainability
T: +49 (0) 6172 608-93873
axel.faupel@fresenius.com
Do you have questions regarding our company and our products and services? Our experts will be happy to help.
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 608-0
Postal address:
Fresenius SE & Co. KGaA
61346 Bad Homburg
Germany
Nick Stone
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com
Kacper Boborykin
Senior Manager Investor Relations
(US based)
T: +1 224 566 1998
kacper.boborykin@fresenius.com
Elisabeth Jung
Senior Manager Investor Relations
T: +49 (0) 6172 608-2421
elisabeth.jung@fresenius.com
Alexandra Graulich
Secretary Group Communications
T: +49 (0) 6172 608-2501
alexandra.graulich@fresenius.com
Contacts for Corporate Topics
Timo Lindemann
T +49 (0) 6172 608-7939
timo.lindemann@fresenius.com
Leif Heussen
T +49 (0) 6172 608-4030
leif.heussen@fresenius.com
Annette Schönleber
T: +49 (0) 6172 608-96847
annette.schoenleber@fresenius.com
Sabine Polte (on parental leave)
T: +49 (0) 6172 608-2395
sabine.polte@fresenius.com
Contacts for Fresenius Kabi
Nicole Meier
T +49 (0) 6172 686-2394
nicole.meier@fresenius.com
Tim-Arne Kuehrt
T +49 (0) 6172 686-4112
tim.kuehrt@fresenius.com
Contacts for Fresenius Helios
Steffen Rinas
T: +49 (0) 6172 608-6698
steffen.rinas@fresenius.com
Birgit Gugath
T +49 (0) 173 28 12 169
birgit.gugath@helios-gesundheit.de
Franziska Vallentin
T +49 (0) 151 65 21 99 81
franziska.vallentin@helios-gesundheit.de
If you have questions regarding our application process or our career opportunities please contact us at karriere@fresenius.com.
You can find detailed contact information on our careers website.
For information on specific products and services, please directly contact our business segments:
Fresenius Kabi
Infusion therapy, clinical nutrition and transfusion technology
Fresenius Helios (German only)
Hospitals and health care prevention
Joachim Weith
Senior Vice President Governmental Affairs & Public Policy
T: +49 (0) 6172 608-2101
GAPP@fresenius.com
Daniela Eyrich
Team Assistant Governmental Affairs & Public Policy
T: +49 (0) 6172 608-2302
daniela.eyrich@fresenius.com
If you have any questions about sustainability, please contact us at the following address: sustainability@fresenius.com
Detailed information on sustainability can be found at Responsibility.
If you have any questions about procurement, please contact us at the following address: zentraleinkauf@fresenius.com
Sebastian Schlagwein
Head of Group ESG
T: +49 (0) 6172 608-2637
sebastian.schlagwein@fresenius.com
Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Karen Janek
Assistant Investor Relations
T: +49 (0) 6172 608-2487
karen.janek@fresenius.com
The Fresenius Group consists of several independently operating business units. Statements reflect analysis performed on products developed by one or several business units.
2024
Publication Date : 19 December 2024
Update Date: -
Fresenius cybersecurity statement for devices tested against the "OpenSSH" CVE-2024-6387 vulnerability.
Publication Date : 10 April 2024
Update Date: 19 December 2024
Fresenius cybersecurity statement for devices tested against the "BLUFFS" vulnerability.
2023
Publication Date : 24 November 2023
Update Date: -
Fresenius cybersecurity statement for devices tested against the "CVE-2022-45611" vulnerability.
2022
Publication Date : 11 July 2022
Update Date: 19 December 2024
Fresenius cybersecurity statement for devices tested against the "MSDT Follina" vulnerability.
Publication Date : 29 June 2022
Update Date: -
Fresenius cybersecurity statement for devices tested against the "Access:7" vulnerability.
2021
Publication Date : 21 December 2021
Latest Update Date: 09 June 2022
Fresenius cybersecurity statement for devices tested against the "Apache Log4J" vulnerability.
Publication Date : 24 November 2021
Latest Update Date: -
Fresenius cybersecurity statement for devices tested against the "NUCLEUS:13" vulnerability.
Publication Date : 12 October 2021
Latest Update Date: -
Fresenius cybersecurity statement for devices tested against the "INFRA:HALT" vulnerability.
2020
Publication Date : 06 July 2020
Update Date: 09 July 2020
Fresenius cybersecurity statement for devices tested against the "Ripple20" vulnerability.
Submit a report
Contact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
cert@fresenius.com